Inhalers Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Inhaler Market: By Devices (Metered Dose Inhaler, Dry Powder Inhaler and Nebulizer), By Type (Preventive Inhaler, Reliever Inhaler and Long-acting Bronchodilators Inhaler), By Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), By End User (Home Care and Hospitals & Clinics), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: , Tag:

Report

Description

Inhalers Market Size is estimated to be valued at USD 19,445.4 Million in 2021 and is poised to grow at a significant CAGR of 4.3% over 2022-2028. Due to an increase in occurrences of respiratory disorders, particularly the diagnosis and treatment of COVID-19, hospital and clinical visits increased considerably, resulting in an increase in demand for inhalers and nebulizers, propelling the market forward. Various collaborations, partnerships, and acquisitions between pharmaceutical companies and smart inhaler manufacturers have increased competition in the smart inhaler industry, and the rise in healthcare expenditure in such economies presents lucrative opportunities for the market; thus, is a great opportunity for key players to invest. Although inhalers have proven to be very successful devices, the wide variety of devices available can make it difficult for physicians to determine which one is best for a certain patient. In the future years, the market will be driven by the rise in popularity of smart respiratory inhaler devices. Smart inhaler devices connect to a smartphone app, allowing users to keep track of dose reminders and prescription schedules.

Recent Market Developments:

In January 2021, Vector Capital announced the acquisition of Mood Media, the world’s top in-store media solutions company dedicated to improving consumer satisfaction.

In July 2020, Novartis received the European Commission (EC) permission for Enerzair Breezhaler, which has the first digital companion (sensor and app) in the EU that can be prescribed alongside asthma medication.

In May 2020, Iconovo received CE mark approval for its capsule-based dry powder inhaler ICOcap for use in clinical trials.

Inhalers Market

MARKET SUMMARY
-
4.3% CAGR
  • Study Period– 2022– 2028
  • Base Year– 2021
  • CAGR– 4.3%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Inhalers Market

  • The report gives comprehensive outlook on inhalers across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report gives historical, current, and future market sizes (US$ Mn) on the basis of device type, application, inhaler type, end user, and region.
Key Players
  • 3M Company (USA)
  • Aradigm Corporation (California)
  • AstraZeneca Plc. (UK)
  • Cipla Inc. (India)
  • GlaxoSmithKline (UK)
Inhalers Market

Dynamics

The rising prevalence of COPD and asthma is a primary driver of market expansion. The number of people aged 65 and above in the United States is expected to nearly treble by 2050, with those aged 85 and up constituting the fastest-growing age group. Patients with asthma and COPD who live longer have more physical and cognitive co-morbidities, which impact their ability to use inhaler devices. As the amount of ozone and particle matter in the air rises, the likelihood of developing asthma symptoms rises at an alarming rate. As a result, an increase in air pollution is predicted to directly contribute to a spike in asthma and COPD cases, propelling the market forward. However, high cost of the products is impelling the market growth.


North-America got significant share

Inhalers Market

The inhaler market in North America is likely to hold a highest revenue share of 39% in 2021 and in the following years, it is predicted to increase at a rapid rate. Better healthcare infrastructure and facilities, a rise in the number of patients suffering from asthma and COPD, acceptance of technologically sophisticated therapies, the presence of major companies, and an increase in healthcare expenditure in the region are all contributing to the region's growth. Furthermore, due to its large senior population, rising disposable incomes, increased healthcare spending, and different developmental activities, Asia-Pacific is expected to be the fastest developing area. Furthermore, in the Asia-Pacific market, India and China are predicted to rise at a fast rate.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast.
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Segmentation

Inhalers Market


Location

GEOGRAPHY

Frequently Asked Questions

The inhalers market is projected to expand at a CAGR of 4.3% during the forecast period.

Europe is the fastest-growing region for inhalers market

3M Company, Aradigm Corporation, AstraZeneca Plc., Boehringer Ingelheim GmbH, Cipla Inc., GlaxoSmithKline


Report

Table Of Content


Report

Company Profile

  • 3M Company (USA)
  • Aradigm Corporation (California)
  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Cipla Inc. (India)
  • GlaxoSmithKline (UK)
  • Novartis AG (Switzerland)
  • PULMATRIX, INC. (USA)
  • Teva Respiratory, LLC. (USA)
  • Mankind Corporation (Califonia)
  • BESPAK (UK)
  • Beximo Pharmaceuticals Limited (Bangladesh)
  • Spyryx Biosciences, Inc. (North Carolina)
  • MidasCare Pharmaceuticals Pvt. Ltd. (India)
  • Omega Life Sciences Ltd. (Isreal)
  • Drive DeVilbiss Healthcare Ltd. (UK)
  • Manta Devices LLC. (Cambridge)
  • Savara Inc. (USA)
  • OMRON Healthcare Europe B.V. (Europe)
  • Hovione LLC. (USA)
  • Koninklijke Philips N.V. (Netherlands)
  • Teijin Limited (Japan)
  • Vitalograph Ltd. (UK)

Description

Inhalers Market Size is estimated to be valued at USD 19,445.4 Million in 2021 and is poised to grow at a significant CAGR of 4.3% over 2022-2028. Due to an increase in occurrences of respiratory disorders, particularly the diagnosis and treatment of COVID-19, hospital and clinical visits increased considerably, resulting in an increase in demand for inhalers and nebulizers, propelling the market forward. Various collaborations, partnerships, and acquisitions between pharmaceutical companies and smart inhaler manufacturers have increased competition in the smart inhaler industry, and the rise in healthcare expenditure in such economies presents lucrative opportunities for the market; thus, is a great opportunity for key players to invest. Although inhalers have proven to be very successful devices, the wide variety of devices available can make it difficult for physicians to determine which one is best for a certain patient. In the future years, the market will be driven by the rise in popularity of smart respiratory inhaler devices. Smart inhaler devices connect to a smartphone app, allowing users to keep track of dose reminders and prescription schedules.

Recent Market Developments:

In January 2021, Vector Capital announced the acquisition of Mood Media, the world’s top in-store media solutions company dedicated to improving consumer satisfaction.

In July 2020, Novartis received the European Commission (EC) permission for Enerzair Breezhaler, which has the first digital companion (sensor and app) in the EU that can be prescribed alongside asthma medication.

In May 2020, Iconovo received CE mark approval for its capsule-based dry powder inhaler ICOcap for use in clinical trials.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX